BRIEF-MEI Pharma Says It Will Not Proceed With Second Capital Return Under 2023 Anson And Cable Car Cooperation Agreement

Reuters04-11

April 11 (Reuters) - MEI Pharma Inc :

* MEI PHARMA INC - NOT TO PROCEED WITH SECOND CAPITAL RETURN UNDER 2023 ANSON AND CABLE CAR COOPERATION AGREEMENT

* MEI PHARMA BOARD OF DIRECTORS ALIGNS ON STRATEGY TO ADVANCE VORUCICLIB AND ME-344

* MEI PHARMA INC - BOARD OF DIRECTORS UNANIMOUSLY AGREED ON A STRATEGIC PLAN TO LEVERAGE RECENT POSITIVE VORUCICLIB AND ME-344 CLINICAL DATA

* MEI PHARMA INC: TO PRIORITIZE CLINICAL DEVELOPMENT OF VORUCICLIB WHILE ENABLING DEVELOPMENT OF A NEW ME-344 FORMULATION FOR PHASE 1 STUDY

* MEI PHARMA INC: PLAN WILL REDUCE SHORT-TERM EXPENDITURES ON ME-344 PROGRAM

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426265523?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-11 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426265523","market":"us","top_or_hot":-1,"title":"BRIEF-MEI Pharma Says It Will Not Proceed With Second Capital Return Under 2023 Anson And Cable Car Cooperation Agreement","media":"Reuters","content":"<html><body><p>April 11 (Reuters) - <a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> Inc   :</p><p>   * MEI PHARMA INC - NOT TO PROCEED WITH SECOND CAPITAL RETURN UNDER 2023 ANSON AND CABLE CAR COOPERATION AGREEMENT</p><p>   * MEI PHARMA BOARD OF DIRECTORS ALIGNS ON STRATEGY TO ADVANCE VORUCICLIB AND ME-344</p><p>   * MEI PHARMA INC - BOARD OF DIRECTORS UNANIMOUSLY AGREED ON A STRATEGIC PLAN TO LEVERAGE RECENT POSITIVE VORUCICLIB AND ME-344 CLINICAL DATA</p><p>   * MEI PHARMA INC: TO PRIORITIZE CLINICAL DEVELOPMENT OF VORUCICLIB WHILE ENABLING DEVELOPMENT OF A NEW ME-344 FORMULATION FOR PHASE 1 STUDY</p><p>   * MEI PHARMA INC: PLAN WILL REDUCE SHORT-TERM EXPENDITURES ON ME-344 PROGRAM</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-MEI Pharma Says It Will Not Proceed With Second Capital Return Under 2023 Anson And Cable Car Cooperation Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-MEI Pharma Says It Will Not Proceed With Second Capital Return Under 2023 Anson And Cable Car Cooperation Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 11 (Reuters) - MEI Pharma Inc   :   * MEI PHARMA INC - NOT TO PROCEED WITH SECOND CAPITAL RETURN UNDER 2023 ANSON AND CABLE CAR COOPERATION AGREEMENT   * MEI PHARMA BOARD OF DIRECTORS ALIGNS ON ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720051017.SGD","symbol_name":"Allianz Global Artificial Intelligence AT Acc H2-SGD","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2426265523","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426265523","pubTimestamp":1712845386,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 11  - MEI Pharma Inc   :   * MEI PHARMA INC - NOT TO PROCEED WITH SECOND CAPITAL RETURN UNDER 2023 ANSON AND CABLE CAR COOPERATION AGREEMENT   * MEI PHARMA BOARD OF DIRECTORS ALIGNS ON STRATEGY TO ADVANCE VORUCICLIB AND ME-344   * MEI PHARMA INC - BOARD OF DIRECTORS UNANIMOUSLY AGREED ON A STRATEGIC PLAN TO LEVERAGE RECENT POSITIVE VORUCICLIB AND ME-344 CLINICAL DATA   * MEI PHARMA INC: TO PRIORITIZE CLINICAL DEVELOPMENT OF VORUCICLIB WHILE ENABLING DEVELOPMENT OF A NEW ME-344 FORMULATION FOR PHASE 1 STUDY   * MEI PHARMA INC: PLAN WILL REDUCE SHORT-TERM EXPENDITURES ON ME-344 PROGRAMSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4588":"碎股","BK4512":"苹果概念","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1861215975.USD":"贝莱德新一代科技基金 A2","BK4139":"生物科技","MEI":"Methode Electronics Inc","LU1548497426.USD":"安联环球人工智能AT Acc","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4141":"半导体产品","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BK4145":"电子制造服务","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","ON":"安森美半导体","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","MEIP":"MEI Pharma"},"translate_title":"简介——梅制药表示，根据2023年安森和缆车合作协议，它不会进行第二次资本回报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEIP":1,"MEI":1,"ON":0.64},"content_text":"April 11 (Reuters) - MEI Pharma Inc   :   * MEI PHARMA INC - NOT TO PROCEED WITH SECOND CAPITAL RETURN UNDER 2023 ANSON AND CABLE CAR COOPERATION AGREEMENT   * MEI PHARMA BOARD OF DIRECTORS ALIGNS ON STRATEGY TO ADVANCE VORUCICLIB AND ME-344   * MEI PHARMA INC - BOARD OF DIRECTORS UNANIMOUSLY AGREED ON A STRATEGIC PLAN TO LEVERAGE RECENT POSITIVE VORUCICLIB AND ME-344 CLINICAL DATA   * MEI PHARMA INC: TO PRIORITIZE CLINICAL DEVELOPMENT OF VORUCICLIB WHILE ENABLING DEVELOPMENT OF A NEW ME-344 FORMULATION FOR PHASE 1 STUDY   * MEI PHARMA INC: PLAN WILL REDUCE SHORT-TERM EXPENDITURES ON ME-344 PROGRAMSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426265523"}